KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palvella Therapeutics (PVLA) Cash & Current Investments (2016 - 2026)

Palvella Therapeutics has reported Cash & Current Investments over the past 10 years, most recently at $59.2 million for Q4 2022.

  • Quarterly Cash & Current Investments fell 49.76% to $59.2 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $59.2 million through Dec 2022, down 49.76% year-over-year, with the annual reading at $59.2 million for FY2022, 49.76% down from the prior year.
  • Cash & Current Investments was $59.2 million for Q4 2022 at Palvella Therapeutics, down from $91.2 million in the prior quarter.
  • Over five years, Cash & Current Investments peaked at $159.6 million in Q1 2018 and troughed at $59.2 million in Q4 2022.
  • The 5-year median for Cash & Current Investments is $95.7 million (2019), against an average of $101.2 million.
  • Year-over-year, Cash & Current Investments soared 200.01% in 2018 and then tumbled 49.76% in 2022.
  • A 5-year view of Cash & Current Investments shows it stood at $125.2 million in 2018, then fell by 16.8% to $104.2 million in 2019, then crashed by 32.37% to $70.4 million in 2020, then skyrocketed by 67.19% to $117.8 million in 2021, then plummeted by 49.76% to $59.2 million in 2022.
  • Per Business Quant, the three most recent readings for PVLA's Cash & Current Investments are $59.2 million (Q4 2022), $91.2 million (Q3 2022), and $80.9 million (Q2 2022).